The fight against the human immunodeficiency virus (HIV) has made great progress since its beginnings but remains a major current medical, scientific, and societal challenge. Adherence to daily medication intake among treated patients is sometimes imperfect. Lenacapavir is a new antiretroviral with a new action mechanism and very long duration of action. Thus, it is a promising new tool in this fight, particularly in pre-exposure prophylaxis of HIV infection.
Keywords
Lenacapavir, antiretroviral, HIV, pre-exposure prophylaxis, adherence